Clinical and Economic Utility of BTK Inhibitors in CLL : Episode 6

Opinion

Video

July 23, 2024

Optimizing Therapy Sequencing in CLL

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD

A panel of experts discuss optimizing therapy sequencing in CLL.

EP: 1.Recent Trends and Innovations in the Management of CLL

EP: 2.CLL Treatment Landscape: Overview of BTK Inhibitors

EP: 3.Evaluating Value of BTK Inhibitors in CLL Treatment

EP: 4.Factors Influencing Choice of Second-Generation BTKi Monotherapy

EP: 5.Empowering Patients: Key Considerations for BTK Inhibitor Adherence

Now Viewing

EP: 6.Optimizing Therapy Sequencing in CLL

EP: 7.Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

EP: 8.Decision-Making in CLL: The Role of Real-World Evidence

EP: 9.Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

EP: 10.Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

EP: 11.Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

EP: 12.The Inflation Reduction Act: Implications for Patient Access in CL

EP: 13.Patient Access Advocacy for BTK Inhibitors

EP: 14.Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following question(s):

How do you determine the optimal sequencing of therapies for patients with CLL?
How does prior therapy exposure influence your choice of subsequent treatments?

Related Content

chronic lymphocytic leukemia | Image credit: LASZLO – stock.adobe.com

January 15th 2025

BTKi Resistance Mechanisms, Solutions Probed at ASH

Jared Kaltwasser

One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor (BTKi) had a key mutation linked to resistance.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Patient with leukemia receiving treatment | Image credit: tonefotografia – stock.adobe.com

January 8th 2025

Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024

Gayle Turim Dickstein

Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.

January 3rd 2025

New Generation of CAR T May Elicit Improved CR Rates in CLL

AJMC Contributor

A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Mehrdad Mobasher, MD, MPH | Image credit: BeiGene

January 2nd 2025

BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024

Mary Caffrey

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.

December 26th 2024

Top 5 Most-Read CLL/SLL Articles of 2024

Christina Mattina

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment efficacy, and more.